Patent Granted in Israel for RECCE Anti-Infectives
Filed with ASX · · 3 pages · English
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
- Recce Receives AUD $11.17m R&D Advance
- Safety Committee Approves Expansion of Ph I/II DFI Trial
- RCE Establishes Strategic Partnership in South-East Asia
- Positive Ph I/II DFI Efficacy Data to Support Site Expansion
Later from Recce Pharmaceuticals
- Recce Pharmaceuticals - Business Update
- Recce Completes 5,000 R327 Doses Per Week under GMP
- Safety Committee Approves High Dose of 4,000mg
- China Patent Granted for RECCE Anti-Infectives
- MCRI Pilot Study- Positive Efficacy Data for Lung Infections
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals